NCT06058546
Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial of Efficacy and Safety of Jiuweihuaban Pill in the Treatment of Moderate to Severe Plaque Psoriasis(Syndrome of Blood-heat ).
Tasly Pharmaceutical Group Co., Ltd·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Plaque Psoriasis
- Drug/Device/Intervention
- Jiuweihuaban Pill placebo
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Location
- Beijing,Changchun,Changsha,Chengdu,Jinan,Kunming,Nanyang,Shenyang,Tianjin,Wenzhou,Xiamen,Xingtai, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Oct 01, 2023
- End date
- Oct 01, 2025
- Enrollment
- 180 participants
Primary outcome
PASI 75
Summary
This study will evaluate the efficacy and safety of Jiuweihuaban Pill in the treatment of
 moderate to severe plaque psoriasis(syndrome of blood-heat ).
ICD-10 classifications
PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06058546
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06058546 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tasly Pharmaceutical Group Co., Ltd and is currently Not yet recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.